



Prof. Dr. med. Martin Dreyling
CCC | LMU Klinikum München

Grußwort & Highlights

Offenlegung potentieller Interessenskonflikte

LymphomKompetenz KOMPAKT – EHA 2025 Mailand, Italien wird in Kooperation mit fünf unterstützenden Firmen durchgeführt.
Meine persönlichen Disclosures betreffen:

Research Support (institution)	Abbvie, Gilead/Kite, Janssen, Lilly, Roche
Employee	-
Major Stockholder	-
Speakers Bureau	-
Speakers Honoraria	Astra Zeneca, Beigene, BMS, Gilead/Kite, Janssen, Lilly, Roche
Scientific Advisory Board	Abbvie, Astra Zeneca, AvenCell, Beigene, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly/Loxo, Novartis, Roche, Sobi

Lymphom Kompetenz KOMPAKT



KML KONGRESSE

Expert:innen berichten zu
Lymphomen & Leukämien



EHA 2025

MAILAND, ITALIEN

12. – 15. Juni 2025



EHA 2025 | Mailand

KML-Berichte sind online ab 15. Juni 2025
www.lymphome.de/eha2025

Highlight 1

Diffuses großzelliges B-Zell-Lymphom (DLBCL)


Polatuzumab Vedotin, Rituximab, Gemcitabine and Oxaliplatin (Pola-R-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results from the Randomized Phase III POLARGO Trial

PRESENTATION ID S101 (Press Conference/Plenary Session)

Dr. Matthew Matasar (New Brunswick, NJ, United States of America)

Highlight 1: Pola-R-GemOx beim R/R DLBCL



POLARGO is a Phase III randomized trial evaluating Pola-R-GemOx versus R-GemOx



*Polatuzumab vedotin (1.8 mg/kg) plus R-GemOx (R, 375 mg/m²; Gem, 1000 mg/m²; Ox, 100 mg/m²). †PET-CT at end of treatment.
INV, investigator; IRC, independent review committee; NOS, not otherwise specified;
ORR, overall response rate; PET-CT, positron emission tomography and computed tomography; Q3W, every 3 weeks.

Highlight 1: Pola-R-GemOx beim R/R


Key secondary endpoints of PFS, CR and ORR were met



*CR and ORR are IRC-assessed at end of treatment. Progression free survival is censored at earliest of NALT or two or more missing tumour assessments. *Stratified for prior lines of systemic therapy (1 vs ≥2), outcome of last systemic therapy (relapsed vs refractory), age (≤70 vs >70 years); †p-value based on Cochran-Mantel-Haenszel method. IRC, independent review committee; NALT, new anti-lymphoma therapy; PR, partial response.

Highlight 1: Pola-R-GemOx beim R/R

Statistically significant survival benefit with Pola-R-GemOx versus R-GemOx



- **40% reduction in relative risk of death with Pola-R-GemOx** compared with R-GemOx
- **Median OS was 19.5 months** with Pola-R-GemOx (vs 12.5 months with R-GemOx)
- 24-month event-free rate was 44.0% with Pola-R-GemOx (vs 33.2% with R-GemOx)

*Stratified for age (≤ 70 vs > 70 years), prior lines of systemic therapy (1 vs ≥ 2) and outcome of last systemic therapy (relapsed vs refractory). CI, confidence interval; HR, hazard ratio.

Lymphom Kompetenz KOMPAKT



KML KONGRESSE

Expert:innen berichten zu
Lymphomen & Leukämien



EHA 2025

MAILAND, ITALIEN

12. – 15. Juni 2025

Das Informationsprojekt wird unterstützt von:

abbvie

AstraZeneca 



A Sandoz Brand

Lilly

Die Firmen hatten keinen Einfluss auf die Inhalte.